E
Elanco
Elanco | Solutions for Protecting and Enhancing Animal Health
About Elanco
The story of Elanco begins not with a founder, but within a pharmaceutical giant. In 1953, Eli Lilly and Company introduced its first antibiotic for veterinary use. This move laid the groundwork for a new division, and in 1954, the company formally organized its animal science activities, led by George Varnes. The name 'Elanco,' short for Eli Lilly and Company, was officially adopted in 1960. For decades, Elanco operated and grew under the Lilly umbrella, expanding globally and building out its portfolio of products for both livestock and pets. A pivotal moment arrived in September 2018, when Elanco held its Initial Public Offering (IPO) on the New York Stock Exchange. This marked the beginning of its separation from Eli Lilly, and by 2019, Elanco was a fully independent company. Now standing on its own, Elanco made a bold, strategic move. In August 2020, it completed the acquisition of Bayer Animal Health for approximately $6.89 billion. This transaction significantly expanded Elanco's scale, particularly in the companion animal market, and positioned it as the world's second-largest animal health company. The deal combined Elanco's strength with veterinarians with Bayer's direct-to-consumer experience, creating a more diversified and formidable player in the industry.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2018
- Employees
- 9,380
- Open positions
- 232
- Dealroom signal
- 82.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology, Innovative Food
- Sector
- Veterinary, Biotechnology, Biotech and Pharma, Pets, DT and LS, observatoire healthtech, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2C
- Investment activity
- 10 companies, latest Feb 2026
- Capital deployed
- $22M
- Preferred round
- ACQUISITION
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Dec 2023 | $250M | — | Ancora | ↗ |
| CORPORATE SPINOUT✓Other financing | Jan 2019 | $0 | — | Eli Lilly | — |
Growth signals
Latest recorded traffic for Elanco is 79K monthly website visits, up 17.9% over the last three months. Elanco's team grew 23.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AHV InternationalZwolle, NetherlandsAHV International empowers farmers through innovation in animal health to built on the principles of quorum sensing
→
AthianIndianapolis, United StatesPress Release: Athian Announces Funded Launch
$16Mvaluation
Kindred BiosciencesSan Francisco, United StatesKindredBio | Bringing the very best science and medicine to our companion animals
$21Mvaluation
Stonehaven IncubateAndermatt, SwitzerlandCommitted to applying disruptive human technology to the animal health space
→
Resilient BioticsDurham, United StatesDeveloping microbiome therapies and using data science for therapeutic discovery
$28Mvaluation
VetoquinolParis, FranceCompany dedicated to global animal health concentrating on livestock, poultry and companion animals
$837Mvaluation
Bayer Animal HealthMonheim am Rhein, Germany
$7.6Bvaluation
Prevtec microbiaMontreal, CanadaCanadian biotechnology company specialized in the development of vaccines and other technologies that help fight against bacterial diseases in food animals
$60Mvaluation
Aratana TherapeuticsLeawood, United StatesDevelops and markets innovative therapeutics for pets
$48Mvaluation
BoragenDurham, United StatesDedicated to providing novel pharmacophores and drug modalities
$8Mvaluation
Elanco in the Indianapolis ecosystem
The Elanco office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Eli Lilly
Ancora
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Elanco on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Elanco’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









